Stack
Tesamorelin and Ipamorelin
The same two-receptor logic as CJC-1295 and ipamorelin, with the one GHRH analogue that has an approved indication behind it.
Tesamorelin is a GHRH analogue approved for HIV-associated lipodystrophy. It is the only compound in this category with a registered indication, and that is why this pairing gets chosen over the CJC-1295 version.
That approval is for tesamorelin alone, at 2 mg daily, for a specific condition. It says nothing about this combination or these doses, and the visceral fat reduction it was approved on was measured in a population that is not the one running this stack.
Ipamorelin contributes the second pathway, exactly as it does alongside CJC-1295.
The schedule
Commonly run, not recommended12 weeks. Doses are what sources describe rather than what we advise — where a source gave a range we show the range instead of choosing a number inside it.
| Compound | Dose | How often | Weeks |
|---|---|---|---|
| TesamorelinApproved for another indicationGHRH analogue with an approved indication behind it, though not this one. | 1 mg–2 mg | Once dailyThe approved dose for lipodystrophy is 2 mg daily. Community use commonly runs lower. | 1–12 |
| IpamorelinEarly human trialsGhrelin receptor agonist, covering the second pathway. | 200 mcg | Once daily | 1–12 |
Things worth knowing
- Tesamorelin's approval is for one condition at one dose. Borrowing its credibility for a different purpose is the main thing to be careful about here.
- Injection site reactions are notably more common with tesamorelin than with the other secretagogues.
- The same growth hormone cautions apply: proliferative signalling, glucose handling, fluid retention.
- Both are prohibited in sport at all times.
Related
Questions
- How is this different from CJC-1295 with ipamorelin?
- It is the same shape of pairing with a much better-evidenced GHRH half. Tesamorelin completed a phase 3 programme and holds an approval for a specific indication; CJC-1295 has neither. That is the largest evidence gap between any two otherwise-comparable compounds on this site.
- Does the approval mean this stack is approved?
- No. Tesamorelin is approved for reducing excess visceral fat in a specific patient population — not for growth hormone support in healthy adults — and not in combination with anything. An approval for one indication says nothing about a different use of the same drug.
- Which one is worth the extra cost?
- Tesamorelin is substantially more expensive per milligram, which is the trade being made. Our price index carries current per-milligram figures for both, and the comparison page sets out what the evidence difference actually is.
This page is educational. It describes what published research reports, not what you should do. Peptides discussed here are largely not approved for human use, and nothing on Bioalmanac is medical advice.